AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
TD Toronto-Dominion Bank
OTGLF CD Projekt SA
HRL Hormel Foods Corp
IPOF Social Capital Hedosophia Holdings Corp VI
NIO NIO Inc
NRT North European Oil Royalty Trust
JNJ Johnson & Johnson
STAG STAG Industrial Inc
TM Toyota Motor Corp
Go

Health Care : Pharmaceuticals | Large Cap Growth
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$54.46
Day's Change
0.45 (0.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
54.60
Day's Low
54.19
Volume
(Average)

Today's volume of 8,454,743 shares is on pace to be in-line with AZN's 10-day average volume of 12,418,274 shares.

8,454,743

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, January 25, 2021
CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia

Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca's CALQUENCE(R) (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival (PFS) for adults with previously treated, high-risk...(BusinessWire)

January 21, 2021
China Jo-Jo Drugstores Hosts the First Suppliers Conference in China

China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that...(PR Newswire)

January 18, 2021
ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or...(BusinessWire)

January 13, 2021
Expecting 40% CAGR for Global mHealth Apps Market Size Will Reach USD 105.4 Billion by 2026: Facts & Factors

Facts and Factors have published a new research report titled "mHealth Apps Market By Type (Fitness, Lifestyle Management, Nutrition & Diet, Women's Health, Medication Adherence, Healthcare Providers/ Payors, Disease Management, and...(Globe Newswire)

AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer

--New non-small cell lung cancer data for TAGRISSO(R) and IMFINZI(R) further demonstrate the impact of treating patients in early stages of the disease AstraZeneca will present new data from across the innovative lung cancer portfolio at the IASLC...(BusinessWire)

January 07, 2021
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALXN, MGLN, FLIR, BEAT; Shareholders Are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...(Globe Newswire)

January 06, 2021
FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease

AstraZeneca's FARXIGA (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type 2 diabetes (T2D). The Food and Drug Administration (FDA) grants...(BusinessWire)

December 21, 2020
ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

AstraZeneca's TAGRISSO(R) (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative...(BusinessWire)

Mentor Capital Initiates COVID-19 Related Investments

Mentor Capital, Inc. (OTCQB: MNTR) announced that it has added a business segment that focuses on the vaccine and associated medical companies involved in the fight against SARS-CoV-2. The initial public companies in the small internal portfolio are...(BusinessWire)

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change

Reportlinker.com announces the release of the report "Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05999220/?utm_source=GNW (Globe Newswire)

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

AstraZeneca's TAGRISSO(R) (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative...(BusinessWire)

December 18, 2020
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Alexion Pharmaceuticals, Inc. - ALXN

https://mma.prnewswire.com/media/443626/Monteverde_Associates_PC_Logo.jpg Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is...(PR Newswire)

Biosimilar Therapeutic Peptides Global Market Report 2020-30: COVID-19 Growth and Change

Reportlinker.com announces the release of the report "Biosimilar Therapeutic Peptides Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05998718/?utm_source=GNW (Globe Newswire)

December 17, 2020
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023

Soft tissue sarcoma (STS) is a rare type of cancer that develops in tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occurring in the muscles, tissues, and blood vessels that protect, support and surround the...(PR Newswire)

December 15, 2020
SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm - ALXN, PS, HBAN, CKH

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning potential violations of the federal securities laws and/or breaches of fiduciary...(Globe Newswire)

December 12, 2020
Alexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Alexion Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - ALXN

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) to AstraZeneca PLC for $60.00 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share is...(BusinessWire)

December 10, 2020
Arthritis Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

Reportlinker.com announces the release of the report "Arthritis Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995334/?utm_source=GNW (Globe Newswire)

Immuno-Oncology Drugs Global Market Report 2020-30: COVID-19 Growth and Change

Reportlinker.com announces the release of the report "Immuno-Oncology Drugs Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995343/?utm_source=GNW The global immuno-oncology drugs market is expected to...(Globe Newswire)

ENHERTU (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Durable Responses with New Data From DESTINY-Breast01 in HER2-positive Metastatic Breast Cancer

--Update shows encouraging landmark survival in exploratory analysis with an estimated three out of four patients alive at 18 months Updated results from the positive DESTINY-Breast01 Phase II trial showed AstraZeneca and Daiichi Sankyo Company...(BusinessWire)

December 09, 2020
How Acute Respiratory Distress Syndrome (ARDS) May Be Affecting COVID-19 Patients

All around the globe, scientists are working hard to develop effective treatments, therapies and vaccines to halt the COVID-19 pandemic. Therapies that are under investigation include drugs that have been used to treat malaria and autoimmune...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.